FrancophonIA/ELRC3.0 huggingface dataset:
English: Treated subjects (N=631) had a median age of 52 years (range: 18 to 70); 54.5% were male; 5.4% were Black; 15.2% had a history of depression or bipolar disorder; 79.1% had baseline HCV RNA levels of at least 800,000 IU/mL; 15.4% had portal fibrosis (F2) and 8.7% had bridging fibrosis (F3); 67.7% had HCV genotype 1a infection; 32.3% had HCV genotype 1b infection.
Latvian: Terapiju saņēmušo pētījuma dalībnieku (N = 631) vecuma mediāna bija 52 gadi (intervāls: no 18 līdz 70 gadu vecumam); 54,5% dalībnieku bija vīrieši; 5,4% dalībnieku bija melnādaini; 15,2% pacientu anamnēzē bija depresija vai bipolāri traucējumi; 79,1% dalībnieku CHV RNS līmenis pirms terapijas uzsākšanas bija vismaz 800 000 SV/ml; 15,4% dalībnieku bija portālā fibroze (F2), bet 8,7% dalībnieku bija tiltveida fibroze (F3); 67,7% pētījuma dalībnieku bija 1.a genotipa CHV infekcija; 32,3% dalībnieku bija 1.b genotipa CHV infekcija.
English: SVR12 for genotype 1-infected treatment-naïve subjects in SAPPHIRE-I
Latvian: SVR12 dati ar 1. genotipa vīrusu inficētiem, iepriekš neārstētiem pacientiem SAPPHIRE I pētījumā
English: Genotype 1a, without cirrhosis dasabuvir + ombitasvir/paritaprevir/ritonavir + ribavirin*
Latvian: 1.a genotips, bez aknu cirozes dasabuvīrs + ombitasvīrs/paritaprevīrs/ritonavīrs + ribavirīns*
English: Y93H H58D, H58P, Y93N NS5B A553T S556G C316Y, M414T, G554S, S556R, G558R, D559G, D559N, Y561H a. Observed in at least 2 subjects of the same subtype.
Latvian: C316Y, M414T, G554S, S556R, G558R, D559G, D559N, Y561H
English: Tacrolimus or sirolimus whole blood concentrations should be monitored upon initiation and throughout co-administration with dasabuvir and ombitasvir/paritaprevir/ritonavir and the dose and/or dosing frequency should be adjusted as needed.
Latvian: Sākot lietot dasabuvīru un ombitasvīru/paritaprevīru/ritonavīru, kā arī visā šo zāļu lietošanas laikā, jāuzrauga takrolima vai sirolimu koncentrācija asinīs un pēc vajadzības jāpielāgo zāļu deva un/vai lietošanas biežums.
English: Target Emergent amino acid substitutionsa
Latvian: Mērķproteīns Saistītās aminoskābju substitūcijasa
English: 300 mg single dose itonavir ombitasvir/paritaprevir/ ritonavir.
Latvian: Viena 300 mg deva dasabuvīrs + ombitasvīrs/ paritaprevīrs/ ritonavīrs paracetamols
English: ALT elevations were asymptomatic and generally occurred during the first 4 weeks of treatment, without concomitant elevations of bilirubin, and declined within approximately two weeks of onset with continued dosing of dasabuvir and ombitasvir/paritaprevir/ritonavir with or without ribavirin.
Latvian: AlAT līmeņa paaugstināšanās bija asimptomātiska un parasti tika novērota terapijas pirmajās četrās nedēļās, turklāt netika novērota vienlaicīga bilirubīna līmeņa paaugstināšanās.
English: AbbVie B.V. Tel: +31 (0)88 322 2843
Latvian: Tel: +31 (0)88 322 2843
English: Subjects with HCV GT4 received ombitasvir/paritaprevir/ritonavir with ribavirin for 12 or 24 Weeks.
Latvian: Pacienti, kam bija CHV GT4 infekcija, 12 vai 24 nedēļas saņēma ombitasvīru/paritaprevīru/ritonavīru un ribavirīnu.
English: • gemfibrozil
Latvian: Gemfibrozils
English: Treated subjects (N = 233) had a median age of 49 years (range: 26 to 69); 10% were Black; 12% had compensated cirrhosis; 66% were treatment-naïve; 32% had failed prior treatment with pegIFN/RBV; 2% had failed prior treatment with sofosbuvir.
Latvian: 10% pacientu bija melnādaini, 12% bija kompensēta ciroze, 66% CHV infekcija vēl nebija ārstēta, 32% iepriekš bija nesekmīgi ārstēti ar pegIFN/RBV un 2% iepriekš bija nesekmīgi ārstēti ar sofosbuvīru.
English: SVR12 for genotype 1b-infected treatment-naïve subjects in PEARL III
Latvian: SVR12 dati ar 1.b genotipa vīrusu inficētiem, iepriekš neārstētiem pacientiem PEARL III pētījumā
English: Mechanism: CYP3A4 induction by phenobarbita l.
Latvian: CYP3A4/P-gp
English: Refer to the Summary of Product Characteristics for ribavirin for additional information.
Latvian: Sīkāku informāciju skatīt ribavirīna zāļu aprakstā.
English: 0.5 mg single dose
Latvian: Viena 0,5 mg deva
English: SVR12 for genotype 1a-infected treatment-naïve subjects in PEARL IV
Latvian: SVR12 dati ar 1.a genotipa vīrusu inficētiem iepriekš neārstētiem pacientiem PEARL IV
English: GT1b dasabuvir and ombitasvir/paritaprevir/ritonavir (12 weeks)
Latvian: GT1b dasabuvīrs un ombitasvīrs/paritepravīrs/ritonavīrs (12 nedēļas)
English: ↓ dasabuvir ↓ ombitasvir ↓ paritaprevir
Latvian: ↓ lamivudīns ↔ dasabuvīrs ↔ ombitasvīrs paritaprevīrs
English: 0.75 mg single dose
Latvian: Everolims Viena 0,75 mg deva
English: Treated subjects (N=394) had a median age of 54 years (range: 19 to 71); 49.0% were prior pegIFN/RBV null responders; 21.8/% were prior pegIFN/RBV partial responders; and 29.2% were prior pegIFN/RBV relapsers; 57.6% were male; 8.1% were Black; 20.6% had a history of depression or bipolar disorder; 87.1% had baseline HCV RNA levels of at least 800,000 IU per mL; 17.8% had portal fibrosis (F2) and 14.5% had bridging fibrosis (F3); 58.4% had HCV genotype 1a infection; 41.4% had HCV genotype 1b infection.
Latvian: 71 gada vecumam); 49,0% pacientu nebija atbildes reakcijas uz iepriekšēju terapiju ar pegIFN/RBV, 21,8% pacientu bija daļēja atbildes reakcija uz iepriekšējo terapiju ar pegIFN/RBV un 29,2% pacientu attīstījās recidīvs pēc iepriekšējās terapijas ar pegIFN/RBV; 57,6% dalībnieku bija vīrieši; 8,1% dalībnieku bija melnādaini; 20,6% pacientu anamnēzē bija depresija vai bipolāri traucējumi; 87,1% dalībnieku CHV RNS līmenis pirms terapijas uzsākšanas bija vismaz 800 000 SV/ml; 17,8% dalībnieku bija portālā fibroze (F2), bet 14,5% dalībnieku bija tiltveida fibroze (F3); 58,4% dalībnieku bija 1.a genotipa CHV infekcija; 41,4% dalībnieku bija 1.b genotipa CHV infekcija.
English: The highest documented single dose of dasabuvir administered to healthy volunteers was 2 g. No study drug-related adverse reactions or clinically significant laboratory abnormalities were observed.
Latvian: Vislielākā dokumentētā dasabuvīra reizes deva, ko lietoja veseli brīvprātīgie, bija 2 g.
English: ANTICANCER AGENTS
Latvian: KONTRACEPCIJAS LĪDZEKĻI
English: Hepatobiliary disorders Frequency unknown
Latvian: Biežums nav zināms Anafilaktiskas reakcijas
English: Note: For laboratory abnormalities refer to Table 4.
Latvian: Laboratorisko rādītāju novirzes skatīt 4. tabulā.
English: randomised, global multicentre, open-label
Latvian: nejaušināts, globāls, atklāts daudzcentru pētījums
English: Genotype 1b, without cirrhosis or with compensated cirrhosis dasabuvir + ombitasvir/paritaprevir/ritonavir
Latvian: 1.b genotips, ar kompensētu aknu cirozi vai bez tās dasabuvīrs + ombitasvīrs/paritaprevīrs/ritonavīrs
English: Three interrupted dasabuvir and ombitasvir/paritaprevir/ritonavir for one to seven days, including one on ethinyloestradiol.
Latvian: Trīs pacienti, no kuriem viena paciente lietoja etinilestradiolu, īslaicīgi pārtrauca dasabuvīra un ombitasvīra/paritaprevīra/ritonavīra lietošanu uz 1-7 dienām.
English: Refer to the tacrolimus or sirolimus Summary of Product Characteristics for additional dosing and monitoring instructions.
Latvian: Papildu norādījumus par takrolima vai sirolima lietošanu un uzraudzību skatīt tā zāļu aprakstā.
English: Co-administration of dasabuvir and ombitasvir/paritaprevir/ ritonavir with rilpivirine once daily should only be considered in patients without known QTprolongation, and without other QTprolongation coadministered medicinal products.
Latvian: ritonavīra lietošana kopā ar rilpivirīnu vienu reizi dienā var tikt apsvērta tikai pacientiem bez
English: The pharmacokinetic properties of the combination of dasabuvir with ombitasvir/paritaprevir/ritonavir have been evaluated in healthy adult subjects and in subjects with chronic hepatitis C. Table 18 shows mean Cmax and AUC of dasabuvir 250 mg twice daily with ombitasvir/paritaprevir/ritonavir 25 mg/150 mg/100 mg once daily following multiple doses with food in healthy volunteers.
Latvian: 18. tabulā redzamas vidējās Cmax un AUC vērtības pēc vairākkārtīgas dasabuvīra lietošanas pa 250 mg divas reizes dienā un ombitasvīra/paritaprevīra/ritonavīra 25 mg/150 mg/100 mg lietošanas vienu reizi dienā kopā ar pārtiku klīniski veseliem brīvprātīgajiem.
English: Treatment duration 12 weeks
Latvian: 12 nedēļu grupa
English: CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Latvian: IZSNIEGŠANAS KĀRTĪBAS UN LIETOŠANAS NOSACĪJUMI
English: 5 mg once daily
Latvian: 5 mg vienu reizi dienā Mehānisms:
English: Rare
Latvian: Bezmiegs
English: CYP3A4 inhibition by ritonavir.
Latvian: UGT1A1, bet ritonavīrs inhibē
English: Arm B: dasabuvir and ombitasvir/paritaprevir/ritonavir
Latvian: B grupa: dasabuvīrs un ombitasvīrs/paritaprevīrs/ritonavīrs
English: Treated subjects (N = 63) had a median age of 51 years (range: 31 to 69); 24% were Black; 19% had compensated cirrhosis; 67% were treatment-naïve; 33% had failed prior treatment with pegIFN/RBV; 89% had HCV genotype 1a infection.
Latvian: 24% bija melnādaini, 19% bija kompensēta aknu ciroze, 67% CHV infekcija vēl nebija ārstēta, 33% iepriekš bija nesekmīgi ārstēti ar pegIFN/RBV, 89% bija 1.a genotipa CHV infekcija.
English: Skin and subcutaneous tissue disorders Very common Pruritus Common
Latvian: Ādas un zemādas audu bojājumi Ļoti bieži
English: Baseline platelet count, median (× 109/L) < 90, n (%) ≥ 90, n (%) Pooled analyses of clinical trials Durability of response Overall, 660 subjects in Phase 2 and 3 clinical trials had HCV RNA results for both the SVR12 and SVR24 time points.
Latvian: Kopējie CHV RNS līmeņa noteikšanas rezultāti gan SVR12, gan SVR24 laika punktos 2. un 3. fāzes klīniskajos pētījumos tika iegūti par 660 pētījumu dalībniekiem.
English: Mechanism: CYP3A4 inhibition by ritonavir and UGT inhibition by paritaprevir, ombitasvir and dasabuvir.
Latvian: CYP3A4, un paritaprevīrs, ombitasvīrs un dasabuvīrs inhibē UGT
English: Exviera 250 mg film-coated tablets
Latvian: Exviera 250 mg apvalkotās tabletes dasabuvirum
English: In genotype 1a, substitutions C316Y, M414T, Y448H, A553T, G554S, S556G/R, and Y561H in HCV NS5B reduced susceptibility to dasabuvir.
Latvian: 1.a genotipa CHV NS5B jutību pret dasabuvīru samazināja C316Y, M414T, Y448H, A553T, G554S, S556G/R
English: Prior pegIFN/RBV null responder Prior pegIFN/RBV partial responder Prior pegIFN/RBV relapser Outcome for subjects without SVR12 On-treatment VF
Latvian: Recidīvs pēc iepriekšējās terapijas ar pegIFN/RBV Iznākums pētījuma dalībniekiem, kuri nesasniedza SVR12
English: Beginning the day after dasabuvir and ombitasvir/paritaprevir/ ritonavir are initiated; reinitiate tacrolimus at a reduced dose based on tacrolimus blood concentrations.
Latvian: Sākot no nākamās dienas pēc tam, kad sākta dasabuvīra un ombitasvīra/paritapre vīra/ritonavīra lietošana, takrolimu atsāk lietot samazinātā devā,
English: Hepatic decompensation and hepatic failure
Latvian: Aknu dekompensācija un aknu mazspēja
English: You should not breastfeed during treatment with Exviera.
Latvian: Exviera lietošanas laikā Jūs nedrīkstat barot bērnu ar krūti.
English: Paritaprevir treatment-emergent variants V36A/M, R155K or D168V were observed in NS3 in 47 subjects.
Latvian: Ar paritaprevīra terapiju saistītie NS3 varianti V36A/M, R155K
English: ↑ keto conazole
Latvian: Ko Exviera satur
English: Phenytoin
Latvian: Duloksetīns
English: In Part 1a, all subjects received dasabuvir and ombitasvir/paritaprevir/ritonavir with ribavirin for 12 or 24 weeks.
Latvian: Visi 1.a daļas pacienti 12 vai 24 nedēļas saņēma dasabuvīru, ombitasvīru/paritaprevīru/ritonavīru un ribavirīnu.
English: • mitotane
Latvian: • mitotāns;
English: dasabuvir and ombitasvir/paritaprevir/ritonavir without ribavirin or with weight-based ribavirin for 12 weeks
Latvian: dasabuvīrs un ombitasvīrs/paritaprevīrs/ritonavīrs bez ribavirīna vai kopā ar ribavirīna devām, kas atkarīgas no ķermeņa masas, 12 nedēļas
English: Refer to the Summary of Product Characteristics of ombitasvir/paritaprevir/ritonavir for its pharmacological properties.
Latvian: Farmakoloģiskās īpašības skatīt ombitasvīra/paritaprevīra/ritonavīra kombinācijas zāļu aprakstā.
English: Overall SVR12 HCV genotype 1a Treatment naïve Prior pegIFN/RBV null responders Prior pegIFN/RBV partial responders Prior pegIFN/RBV Prior relapsers HCV genotype 1b Treatment naïve Prior pegIFN/RBV null responders Prior pegIFN/RBV partial responders Prior pegIFN/RBV Prior relapsers Outcome for subjects without SVR12 On-treatment VF Relapse Other a. 97.5% confidence intervals are used for the primary efficacy endpoints (overall SVR12 rate); 95% confidence intervals are used for additional efficacy endpoints (SVR12 rates in HCV genotype 1a and 1b-infected subjects).
Latvian: Cits a. Primārās efektivitātes mērķa kritērijiem (kopējais SVR12 rādītājs) ir izmantoti 97,5% ticamības intervāli; efektivitātes papildu mērķa kritērijiem (SVR12 rādītājs ar 1.a genotipa un 1.b genotipa CHV inficētiem pētījuma dalībniekiem) izmantoti 95% ticamības intervāli.
English: Selected treatment emergent laboratory abnormalities
Latvian: Noteiktas ārstēšanas rezultātā radušās laboratorisko rādītāju novirzes
English: Exviera contains lactose
Latvian: Exviera satur laktozi
English: THYROID HORMONES Levothyroxin e
Latvian: VAIROGDZIEDZERA HORMONI
English: paritaprevir the risks (see section
Latvian: Vienlaicīga lietošana ir kontrindicēta (skatīt
English: dasabuvir and ombitasvir/paritaprevir/ritonavir without ribavirin for 12 weeks
Latvian: dasabuvīrs un ombitasvīrs/paritaprevīrs/ritonavīrs bez ribavirīna 12 nedēļas
English: Apalutamide
Latvian: Atazanavīrs
English: SAPPHIRE-I - genotype 1, treatment-naïve, without cirrhosis
Latvian: SAPPHIRE I - 1. genotipa vīruss, iepriekš neārstēti pacienti bez aknu cirozes Dizains:
English: Treated subjects (N = 22) had a median age of 54 years (range: 34 to 68); 41% were Black; 14% had compensated cirrhosis; 86% were HCV treatment-naïve; 14% had failed prior treatment with pegIFN/RBV; 68% had HCV genotype 1a infection.
Latvian: 41% pacientu bija melnādaini, 14% bija kompensēta ciroze, 86% CHV infekcija vēl nebija ārstēta, 14% iepriekš bija nesekmīgi ārstēti ar pegIFN/RBV un 68% bija 1.a genotipa CHV infekcija.
English: Mechanism: possibly due to UGT inhibition by paritaprevir, ombitasvir and dasabuvir.
Latvian: Mehānisms: dasabuvīra iedarbības pastiprināšanā s, iespējams, tādēļ, ka trimetoprims inhibē dasabuvīrs + ombitasvīrs/ paritaprevīrs/ ritonavīrs
English: Arm A: dasabuvir and ombitasvir/paritaprevir/ritonavir + RBV (12 weeks)
Latvian: A grupa: dasabuvīrs un ombitasvīrs/paritaprevīrs/ritonavīrs + RBV (12 nedēļas)
English: OPIOIDS Methadone
Latvian: Ne metadona,
English: 600/300 mg once daily dasabu vir +
Latvian: 300 mg vienu reizi dienā dasabuvīrs + ombitasvīrs/
English: The activity of dasabuvir was reduced by 5- and 11-fold by C316N and S556G, respectively; 46-fold by M414T or Y448H; and 1569-fold by the C316Y substitutions in the genotype 1b replicon.
Latvian: un S556G substitūcijas; 46 reizes - M414T vai Y448H, 1569 reizes - C316.
English: HCV Genotype 1a dasabuvir and ombitasvir/paritaprevir/ritonavir with RBV
Latvian: CHV 1.a genotips dasabuvīrs un ombitasvīrs/ paritaprevīrs/ ritonavīrs ar RBV
English: dasabuvir + ombitasvir/paritaprevir/ritonavir was administered as multiple doses in all the drug interaction studies except the drug interaction studies with carbamazepine, gemfibrozil, ketoconazole, and sulfamethoxazole/trimethoprim.
Latvian: Visos zāļu mijiedarbības pētījumos, izņemot zāļu mijiedarbības pētījumus ar karbamazepīnu, gemfibrozilu, ketokonazolu un sulfometoksazolu/trimetoprimu, tika lietotas vairākkārtīgas dasabuvīra un ombitasvīra/paritaprevīra/ritonavīra devas.
English: Cyclobenzap rine 5 mg single dose
Latvian: MIORELAKSANTI Karisoprodols viena 250 mg deva
English: Other
Latvian: Cits
English: Tel: +40 21 529 30 35
Latvian: AbbVie S.R.L. Tel: +40 21 529 30 35
English: Dasabuvir should not be used in patients with moderate to severe hepatic impairment (Child-Pugh B or C) (see sections 4.2, 4.3, 4.8 and 5.2).
Latvian: klase pēc Child-Pugh) (skatīt 4.2., 4.3., 4.8. un 5.2. apakšpunktu).
English: PC:
Latvian: gp.
English: Sirolimus
Latvian: Sulfasalazīns
English: Smephenytoin Mechanism: CYP2C19 induction by ritonavir.
Latvian: S-mefenitoīns Mehānisms: ritonavīrs inducē
English: dasabu vir + Ombita svir/par itaprevi r /ritonav ir
Latvian: dasabuvīrs + ombitasvīrs/ paritaprevīrs/ ritonavīrs rosuvastatīns
English: Dose normalized sirolimus ratios are shown for interaction with ombitasvir/paritaprevir/ritonavir + dasabuvir.
Latvian: Nepieciešama sirolima devu attiecības normalizēšana tā mijiedarbības dēļ ar ombitasvīru/paritaprevīru/ritonavīru un dasabuvīru.
English: Treatment outcome dasabuvir and ombitasvir/paritaprevir/ritonavir with RBV for 12 weeks n/N % 95% CI
Latvian: Dasabuvīrs un ombitasvīrs/paritaprevīrs/ritonavīrs kopā ar RBV 12 nedēļas n/N
English: OATP/BCRP /P-gp inhibition by ciclosporin.
Latvian: P-gp inhibīcija s dēļ.
English: ombitas vir/parit aprevir/r itonavir omeprazole
Latvian: dasabuvīrs + ombitasvīrs/ paritaprevīrs/ ritonavīrs omeprazols
English: Posology
Latvian: Darunavīrs
English: Fluvastatin
Latvian: LIETOTS
English: buprenorphin e/ naloxone 4-24 mg/16 mg once daily8
Latvian: 4-24 mg/ 1-6 mg vienu reizi dienā5 Mehānisms: ritonavīrs inhibē
English: Some patients have reported feeling very tired when taking Exviera with other medicines for their hepatitis C infection.
Latvian: Transportlīdzekļu vadīšana un mehānismu apkalpošana Daži pacienti pēc Exviera un citu C hepatīta ārstēšanai paredzēto zāļu vienlaicīgas lietošanas ir sūdzējušies par stipru noguruma sajūtu.
English: No dose adjustment is necessary for raltegravir or dasabuvir ombitasvir/paritaprevir/ ritonavir.
Latvian: Raltegravīra vai dasabuvīra + ombitasvīra/ paritaprevīra/ ritanovīra devas pielāgošana nav nepieciešama.
English: Anaemia
Latvian: Astēnija
English: ombitas vir/parit aprevir/r itonavir cyclobenzap rine
Latvian: paritaprevīrs/ ritonavīrs ciklobenzaprīn s
English: PEARL-II - genotype 1b, pegIFN+RBV-experienced, without cirrhosis Design:
Latvian: PEARL II - 1.b genotipa vīruss, ar peginterferonu + ribavirīnu iepriekš ārstēti pacienti bez aknu cirozes
English: Overall SVR12 HCV genotype 1a HCV genotype 1b Outcome for subjects without SVR12 On-treatment VFa Relapse Otherb a. Confirmed HCV ≥ 25 IU/mL after HCV RNA < 25 IU/mL during treatment, confirmed 1 log10 IU/mL
Latvian: Citsb a. Pierādīts CHV RNS līmenis ≥ 25 SV/ml pēc tam, kad terapijas laikā panāktais CHV RNS līmenis bija < 25 SV/ml, tika pierādīts CHV RNS līmeņa paaugstinājums par 1 log10 SV/ml, salīdzinot ar zemāko līmeni, vai CHV RNS līmenis pastāvīgi bija ≥ 25 SV/ml vismaz 6 terapijas nedēļas.
English: Esomeprazol e
Latvian: PRETSĒNĪŠU LĪDZEKĻI
English: Rosuvastatin
Latvian: ritonavīrs
English: 5 days after completion of dasabuvir + ombitasvir/paritaprevir/ ritonavir treatment, the sirolimus dose and dosing frequency prior to receiving dasabuvir ombitasvir/paritaprevir/ ritonavir should be resumed, along with routine monitoring of sirolimus blood concentrations.
Latvian: paritaprevīra/ ritonavīra terapijas pabeigšanas, jāatsāk tādas pašas sirolima devas un dozēšanas biežumu kādas tās bija pirms dasabuvīra un ombitasvīra/ paritaprevīra/
English: ANTIHYPERLIPIDAEMICS Gemfibrozil
Latvian: DIURĒTISKIE LĪDZEKĻI Furosemīds
English: The SVR12 rates in HCV/HIV-1 co-infected subjects were thus consistent with SVR12 rates in the phase 3 trials of HCV mono-infected subjects.
Latvian: Tas nozīmē, ka SVR12 sastopamība dalībniekiem ar vienlaicīgu CHV/HIV-1 infekciju atbilda SVR12 datiem
English: Mechanism: increase in dasabuvir possibly due to CYP2C8 inhibition by trimethoprim ombitasvir
Latvian: Gemfibrozils 600 mg divas reizes dienā Mehānisms: dasabuvīra iedarbības intensitātes palielināšanās CYP2C8
English: Treated subjects (N=380) had a median age of 58 years (range: 21 to 71); 42.1% were treatment-naïve, 36.1% were prior pegIFN/RBV null responders; 8.2% were prior pegIFN/RBV partial responders, 13.7% were prior pegIFN/RBV relapsers; 70.3% were male; 3.2% were Black; 14.7% had platelet counts of less than 90 x 109/L; 49.7% had albumin less than 40 g/L; 86.1% had baseline HCV RNA levels of at least 800,000 IU/mL; 24.7% had a history of depression or bipolar disorder; 68.7% had HCV genotype 1a infection, 31.3% had HCV genotype 1b infection.
Latvian: 70,3% dalībnieku bija vīrieši; 3,2% dalībnieki bija melnādaini; 14,7% dalībnieku trombocītu skaits bija mazāks par 90 x 109/l; 49,7% dalībnieku albumīna līmenis bija zemāks par 40 g/l; 86,1% dalībnieku CHV RNS līmenis pirms terapijas uzsākšanas bija vismaz 800 000 SV/ml; 24,7% pacientu anamnēzē bija depresija vai bipolāri traucējumi; 68,7% dalībnieku bija 1.a genotipa CHV infekcija; 31,3% dalībnieku bija
English: Dasabuvir M1 AUC values were 6% lower, 10% lower, and 13% lower, respectively.
Latvian: 6%, 10% un 13% zemākas.
English: Treatment outcome dasabuvir and ombitasvir/paritaprevir/ritonavir with RBV 12 weeks
Latvian: Dasabuvīrs un ombitasvīrs/paritaprevīrs/ritonavīrs kopā ar RBV 12 nedēļas
English: dasabuvir and ombitasvir/paritaprevir/ritonavir with weight-based ribavirin for 12 or 24 weeks
Latvian: dasabuvīrs un ombitasvīrs/paritaprevīrs/ritonavīrs kopā ar ribavirīna devām, kas atkarīgas no ķermeņa masas, 12 vai 24 nedēļas
English: 400 mg once daily
Latvian: 200 mg vienu reizi dienā/
English: HCV Genotype 1b dasabuvir and ombitasvir/paritaprevir/ritonavir
Latvian: CHV 1.b genotips dasabuvīrs un ombitasvīrs/ paritaprevīrs/ ritonavīrs
English: Duloxetine 60 mg single dose dasabu vir + ombitas vir/parit aprevir/ ritonavi r duloxetine
Latvian: Viena 60 mg deva dasabuvīrs + ombitasvīrs/ paritaprevīrs/ ritonavīrs dulkosetīns
English: dasabuvir and ombitasvir/paritaprevir /ritonavir + ribavirin
Latvian: dasabuvīrs + ombitasvīrs/ paritaprevīrs/ ritonavīrs rilpivirins
English: dasabuvir and ombitasvir/paritaprevir/ritonavir for 8 weeks Treated subjects (N=166) had a median age of 53 years (range: 22 to 82); 56.6% were female; 3.0% were Asian; 0.6% were Black; 7.2% had baseline HCV RNA levels of at least 6,000,000 IU per mL;
Latvian: dasabuvīrs un ombitasvīrs/paritaprevīrs/ritonavīrs 8 nedēļas Ārstētām pētāmām personām (N=166) vecuma mediāna bija 53 gadi (robežās no 22 līdz 82); 56,6% bija sievietes; 3,0% bija mongoloīdās rases pārstāvji; 0,6% bija melnādainie; 7,2% sākotnēji CHV RNS līmenis bija vismaz 6 000 000 SV/ml; 9% bija progresējusi fibroze (F3) un 98,2% bija CHV 1.b genotipa infekcija (pa vienai pētāmai personai bija 1.a, 1.d un 6. genotipa infekcija).
English: ↔ nor ethindrone
Latvian: Etinilestradiol s/
English: NA Concomitant use is contraindicated (see the Summary of Product Characteristics for
Latvian: N/A Vienlaicīga lietošana ir kontrindicēta (skatīt ombitasvīra/ paritaprevīra/ ritanovīra zāļu aprakstu).
English: Mechanism: Effect on dasabu vir + ombitas vir/parit aprevir/ ritonavi r tacrolimus
Latvian: Mehānisms: ritonavīrs dasabuvīrs + ombitasvīrs/ paritaprevīrs/ ritonavīrs amlodipīns
English: Тел.
Latvian: ATĶ
English: ombitasvir
Latvian: Dabigatrāns
English: 5 mg single dose
Latvian: Viena 5 mg deva
English: NARCOTIC ANALGESICS Paracetamol (given as fixed dose hydrocodone /paracetamol dasabu vir +
Latvian: AUC Ctrough Klīniskie komentāri hidrokodona un paracetamola devu)
English: Mechanism: UGT1A1 inhibition by paritaprevir, ombitasvir and dasabuvir.
Latvian: Mehānisms: paritaprevīrs, ombitasvīrs un dasabuvīrs inhibē
English: Mechanism: OATP1B inhibition by paritaprevir and BCRP inhibition by dasabuvir paritaprevir, and ritonavir.
Latvian: OATP1B un dasabuvīrs, paritaprevīrs un ritonavīrs inhibē KVRP.
English: Pitavastatin
Latvian: Kopovidons
English: Mechanism: CYP3A inhibition by ritonavir.
Latvian: Mehānisms: ritonavīrs inhibē
English: dasabu vir + ombitas vir/parit aprevir/ ritonavi r everolimus
Latvian: dasabuvīrs + ombitasvīrs/ paritaprevīrs/ ritonavīrs etinilestradiols
English: 5 mg single dose and other vitamin K antagonists dasabu vir +
Latvian: Viena 5 mg deva dasabuvīrs + ombitasvīrs/ paritaprevīrs/ ritonavīrs zolpidēms
English: Mechanism: CYP3A4 induction by apalutamide, enzalutamide or mitotane.
Latvian: Mehānisms: apalutamīds, enzalutamīds vai mitotāns inducē
English: Dasabuvir must always be administered together with ombitasvir/paritaprevir/ritonavir .
Latvian: Dasabuvīru lieto kopā ar ombitasvīru/paritaprevīru/ritonavīru.